Clinical trials: Influenza Virus
Influenza, Flu
Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years
This was a blind-observer, monocenter, randomized, comparative, Phase IV study designed to evaluate the immunogenicity and safety of the Sanofi Pasteur Shenzhen Trivalent Influenza Vaccine (SP Shz TIV) versus the Trivalent…
- Trial name
- NCT03344029
- Testing
- SP Shz TIV, Hualan TIV
- Where
- China
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
The objectives of this study were: To describe the safety of each dosage of high-dose quadrivalent influenza vaccine (QIV-HD) used in the study during the 28 days following each vaccination, and serious adverse events (including…
- Trial name
- QHD04 (NCT03698279)
- Testing
- High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)
- Where
- 16 sites in United States, Canada
- Volunteers
- 665 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation)
The clinical trial was conducted in Jintan City of Jiangsu Province, China in May, 2006. The purpose of the clinical trial was to evaluate the safety and immunogenicity against Hualan's Influenza Vaccine (Split Virion)…
- Trial name
- NCT01554813
- Testing
- Influenza split vaccine of 15 μg HA, Influenza split vaccine
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Engineering, Inc.
Influenza
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children
This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in children compared to two other influenza vaccines.
- Trial name
- NCT01198756
- Testing
- Quadrivalent seasonal influenza vaccine GSK2282512A, Fluarix™ VB, Fluarix™ YB
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 3,109 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
The purpose of this study was to evaluate dose-related safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine, administered to healthy children aged 6 to…
- Trial name
- NCT00336453
- Testing
- Influenza Vaccination
- Where
- 3 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 21 to 64 years of age.
- Trial name
- NCT01934127
- Testing
- Investigational H7N1 vaccine GSK2789869A, Investigational H7N1 vaccine GSK2789868A
- Where
- 9 sites in United States, Canada
- Volunteers
- 427 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults
The purpose of this study is to characterize the safety and immunogenicity of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A when co-administered with the seasonal flu vaccine in adults 19 to 40 years of age.
- Trial name
- NCT00985673
- Testing
- GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV)
- Where
- 7 sites in United States, Canada
- Volunteers
- 611 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
The purpose of this study is to characterize the safety, immunogenicity, and relative efficacy of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older.
- Trial name
- NCT00979602
- Testing
- GSK2340274A, GSK2340273A
- Where
- 38 sites in United States, Canada
- Volunteers
- 4,048 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China
The main purpose of this trial is to describe the product profile in terms of immunogenicity and safety following administration of trivalent influenza vaccine (split-virion, inactivated) produced at Shenzhen (SP Shz TIV).
- Trial name
- NCT02228980
- Testing
- Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
- Where
- China
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)
The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and TIV against homotypic and heterotypic influenza virus strains.
- Trial name
- NCT00111579
- Testing
- CAIV-T, TIV
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years
A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years
- Trial name
- NCT00825162
- Testing
- CSL Limited Influenza Virus Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 1,992 people, healthy volunteers welcome
- Sponsor
- Seqirus
Upper Respiratory Tract Infections, Rhinopharyngitis
Effect of the Consumption of a Fermented Milk on Common Infections in Adults Submitted to Multi-stressor Situation
This multicentric, randomized, double-blind and controlled study aims to examine the effect of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel® = tested product) on the incidence of…
- Conditions
- Upper Respiratory Tract Infections, Rhinopharyngitis, Sore Throat, Sinusitis
- Trial name
- NCT01315418
- Testing
- 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®), 2-Non fermented dairy product (control)
- Where
- France
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
Influenza A H1N1
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
A total of up to 90 participants may be given H1N1 influenza challenge virus. In Part A, 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2).
- Trial name
- NCT05572450
- Testing
- Infectious Titre 1, Infectious Titre 2, Infectious Titre 3
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hvivo
Influenza
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.
- Trial name
- NCT03076385
- Testing
- VAL-506440
- Where
- Germany
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine
This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
- Trial name
- NCT07291635
- Testing
- Recombinant Influenza vaccine candidate, Commercial Influenza vaccine
- Where
- 7 sites in Canada
- Volunteers
- 728 people, healthy volunteers welcome
- Sponsor
- Aramis Biotechnologies Inc.
Influenza Vaccine Effectiveness
A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age
This is a post-marketing case-controlled study of the effectiveness of a quadrivalent live attenuated influenza vaccine (Q/LAIV/FluMist® Quadrivalent) versus Inactivated Influenza Vaccine (IIV) and No Vaccine in subjects 2-17…
- Trial name
- ICICLE (NCT01997450)
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 4,121 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.
This study will evaluate the safety of Tamiflu, when used for the prevention of influenza in children during the flu season. Children who would benefit from influenza prophylaxis when influenza is circulating in the community…
- Trial name
- NCT00412555
- Testing
- oseltamivir [Tamiflu]
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
COVID-19, Influenza
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
- Trial name
- NCT06694389
- Testing
- mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine
- Where
- 44 sites in Japan, South Korea and 1 more
- Volunteers
- 2,457 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza Virus Infection
To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection
To evaluate the antiviral effect of TG-1000 compared with placebo in adult patients with acute uncomplicated influenza virus infection.
- Trial name
- NCT04706468
- Testing
- TG-1000
- Where
- China
- Volunteers
- 202 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Influenza
Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
The aim of the study is to evaluate the safety and immunogenicity of the 2011-2012 formulation of Fluzone and Fluzone High-Dose vaccines in participants aged 65 years and older.
- Trial name
- NCT01430819
- Testing
- Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
- Where
- 6 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.